Xiao Pan

Dr. Xiao Pan

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

27 January 2020 in Journal of the American Society for Mass Spectrometry
Verified
Journal Article
Closed access
XPXiao Pan
Xiao Pan
PLPatanachai Limpikirati
Patanachai Limpikirati
HCHuan Chen
Huan Chen
TLTianying Liu
Tianying Liu
RVRichard W. Vachet
Richard W. Vachet

30 April 2020 in Journal of the American Society for Mass Spectrometry
Verified
Journal Article
Closed access
PLPatanachai K. Limpikirati
Patanachai K. Limpikirati
BZBo Zhao
Bo Zhao
XPXiao Pan
Xiao Pan
SEStephen J. Eyles
Stephen J. Eyles
RVRichard W. Vachet
Richard W. Vachet

7 December 2022 in Journal of the American Society for Mass Spectrometry
Verified
Journal Article
Closed access
XPXiao Pan
Xiao Pan
TTThomas Tran
Thomas Tran
ZKZachary J. Kirsch
Zachary J. Kirsch
LTLynmarie K Thompson
Lynmarie K Thompson
RVRichard W. Vachet
Richard W. Vachet

28 October 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SLShukun Luo
Shukun Luo
JBJoshua Bulos
Joshua Bulos
RURicky Uroza
Ricky Uroza
YZYimeng Zhao
Yimeng Zhao
XPXiao Pan
Xiao Pan
MSMohammed Shameem
Mohammed Shameem
Background: Photostability assessment is a critical component in the development of drug products, particularly for antibody–drug conjugates (ADCs) containing light-sensitive small molecules such as camptothecin (CPT) and its derivatives. ADCs conjugated with CPT derivative payloads often require extensive formulation and drug product development to ensure product stability due to their unique light-induced degradation pathways. In this study, we assessed the photostability of two ADC molecules with a CPT derivative payload (deruxtecan, DXd). Methods: Following light exposure, the stability of ADCs was assessed by examining critical quality attributes, such as aggregation and photodegradation products of the antibody, payload, and formulation excipients, using advanced liquid chromatography and mass spectrometry techniques. Results: Our results revealed key degradation pathways, including the formation of high-molecular-weight (HMW) species, payload degradation, and post-translational modifications (PTMs) on amino acid residues in the antibodies. Additionally, the DXd payload amplified the photosensitivity of the formulation solution, leading to histidine degradation in the formulation buffer and subsequent pH changes. To enhance the stability of ADCs for manufacturing and therapeutic use, we developed a robust formulation by systematic buffer screening and a targeted evaluation of selected antioxidant excipients. Further investigations into light conditions revealed that DXd ADCs are particularly sensitive to short-wavelength light. When evaluating the container closure system, it was demonstrated that using amber vials is a viable option for protecting against light-induced degradation. Conclusions: This report outlines a comprehensive strategy to address photo instability in DXd ADC drug product development, focusing on formulation optimization, controlled manufacturing light settings, and the option of using protective containers to ensure product stability.

28 December 2021 in Analytical Chemistry
Verified
Journal Article
Closed access
XPXiao Pan
Xiao Pan
ZKZachary J. Kirsch
Zachary J. Kirsch
RVRichard W. Vachet
Richard W. Vachet